Novel gene therapy strategy to accomplish growth factor modulation induces enhanced tumor cell chemosensitivity

Clinical Cancer Research

Volumn 2, Issue 7, 1996, Pages 1089-1095

  Barnes, Mack N ^a   Deshane, Jessy S ^a   Siegal, Gene P ^a   Alvarez, Ronald D ^a   Curiel, David T ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR; MEMBRANE PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL DEATH; CHEMOSENSITIVITY; COMPLICATION; DRUG INDUCED DISEASE; GENE EXPRESSION; GENE THERAPY; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; TARGET CELL; TUMOR CELL;

CISPLATIN; DOWN-REGULATION; FEMALE; GENE THERAPY; HUMANS; IMMUNOGLOBULIN FRAGMENTS; NEOPLASMS; RECEPTOR, ERBB-2; TUMOR CELLS, CULTURED;

EID: 0029893166     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Bargmann, C., Hung, M., and Weinberg, R. The neu oncogene encodes an epidermal growth factor receptor related protein. Nature (Lond.), 319: 226-229, 1986.
2. Hudziak, R. M., Schlessinger, J., and Ullrich, A. Increased expression of the putative growth factor p185HER2 causes transformation and tumorigenesis of NIH3T3 cells. Proc Natl. Acad. Sci. USA, 84: 7159-7163, 1987
3. Noguchi, M., Murakami, M., Bennett, W., Lupu, R., Hui, F., Harris, C. C., and Gerwm, B. I. Biological consequences of overexpression of a transfected c-erbB-2 in immortalized human bronchial epithelial cells. Cancer Res., 53: 2035-2043, 1993.
4. Muller, W. J., Sinn, E., Pattengale, P. K., Wallace, R., and Leder, P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell, 54: 105-115, 1988.
5. Slamon, D. J., Godolphm, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., and Press, M. F. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (Washington DC), 244: 707-713, 1989.
6. Tsai, C. M., Yu, D. Chang, K. T., Wu, L. H., Perng, R. P., Ibrahim, N. K., and Hung, M. C. Enhanced chemoresistance by elevation of p185neu levels in HER/neu-transfected human lung cancer cells. J. Natl. Cancer Inst., 87. 682-684, 1995.
7. Tsai, C. M., Chang, K. T., and Perng, R. P. Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/ neu gene expression but not with ras gene mutations J Natl. cancer Inst, 85: 897-901, 1993.
8. HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc. Natl. Acad. Sci. USA, 84: 7159-7163, 1987.
9. Hung, M. C., Zhang, X., Yan, D. H., Zhang, H. Z., He, G. P., Zhang, T. Q.. and Shi, D. R. Aberrant expression of the c-erbB-2/neu protooncogene in ovarian cancer. Cancer Lett., 61: 95-103, 1992.
10. Berchuck, A , Kamel, A , Whitaker, R., Bigotti, A., Ventro, I., Slamon, D. J., Fendly, B. M., Dodge, R., Clarke-Pearson, D. L., and Marks, P. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res , 50: 4087-4091, 1990.
11. Hynes, N. E. Amplification and overexpression of the erbB-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy. Cancer Biol., 4. 19-26, 1993.
12. Felip, E., Del Campo, J. M., Rubio, D., Vidai, M. T., Colomer, R , and Bermejo, B. Overexpression of c-erbB-2 in epithelial ovarian cancer, prognostic value and relationship with response to chemotherapy. Cancer (Phila ), 75: 2147-2152, 1995.
13. Benz, C., Scott, G., Sarup, J., Johnson R., Tripathy, D., Coronado, E., Shepard, H., and Osborne, C Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res. Treat., 24: 85-95, 1993.
14. Hancock, M. C., Langten, B. C., Chan, T., Toy, P., Monahan, J. J., Mischak, R. P., and Shawver, L. K A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res., 51: 4575-4580, 1991.
15. Arteaga, C. L., Winnier, A. R., Poirier, M C., Lopez-Larraza, D. M., Shawver, L. K., Hurd, S. D., and Stewart, S. J p185c-erbB-2 signaling enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res., 54: 3758-3765, 1994.
16. Pietras, R. J., Fendly, B. M , Chazin, V. R., Pegram, M. D., Howell, S. B., and Slamon, D. J Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene, 9: 1829-1838, 1994.
17. Paik, S. Clinical significance of erbB-2 (HER-2/neu) protein. Cancer Invest., 10: 575-579, 1992.
18. Deshane, J., Loechel, F., Conry, R. M., Siegal, G. P., King, C. R., and Curiel, D. T. Intracellular single-chain antibody directed against erbB-2 down regulates cell surface erbB-2 and exhibits a selective antiproliferative effect in erbB-2 overexpressing cell lines. Gene Ther., 1: 332-337, 1994.
19. Beerli, R. R., Winfried, W., and Hynes, N. E. Intracellular expression of single chain antibodies reverts erbB-2 transformation. J. Biol. Chem., 269: 23931-23936, 1994.
20. Deshane, J., Cabrera, G , Grim, J. E , Siegal G. P., Pike, J., Alvarez, R. D., and Curiel, D. T. Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody. Gynecol. Oncol., 59: 8-14, 1995.
21. Deshane, J., Grim, J., Loechel, S., Siegal, G. P., Alvarez, R. D., King, C. R., and Curiel, D. T. Intracellular antibody directed against erbB-2 mediated targeted tumor cell eradication by inducing apoptosis. Cancer Gene Ther., 3: 89-98, 1996.
22. Curiel, D. T., Wagner, E., Cotton, M., Bimstiel, M L., Agarwal, S., and Li, C. M. High-efficiency gene transfer mediated by adenovirus coupled to DNA-polylysine complexes. Hum. Gene Ther., 3: 147-154, 1992.
23. Cristiano, R. J., Smith, L. C., Kay, M. A., Bnnkley, B. R., and Woo, S. L. Hepatic gene therapy: efficient gene delivery and expression in primary hepatocytes utilizing a conjugated adenovirus-DNA complex. Proc. Natl. Acad. Sci. USA, 90: 11548-11552, 1993
24. Curiel, D. T Methods for gene transfer using DNA-adenovirus conjugates. In: Paul A. Robbins (ed.), Methods for Gene Therapy. Totowa, NJ: Humana Press, in press.
25. Graus-Porta, D., Beerli, R R., and Hynes, N. E. Single-chain antibody-mediated intracellular retention of erbB-2 impairs neu differentiation factor and epidermal growth factor signaling. Mol. Cell. Biol., 15: 1182-1191, 1995.
26. Furman, P. A., McGuirt, P. V., Keller, P. M., Fyfe, J. A., and Elion, G. B. Inhibition by acyclovir of cell growth and DNA synthesis of cells biochemically transformed with herpes virus genetic information. Virology, 102: 420-430, 1980.
27. Borrelli, E., Heyman, R., Hsi, M., and Evans, R. M. Targeting of an inducible toxic phenotype in animal cells. Proc. Natl Acad. Sci. USA, 85: 9676-9680, 1992.
28. Huber, B. E , Richards, C. A., and Krenitsky, T. A. Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc. Natl. Acad. Sci. USA, 88: 8039-8043, 1991.
29. Mullen, C. A., Kilstrup, M , and Blaese, R. M Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc. Natl. Acad. Sci USA. 89: 33-37, 1992.
30. Dimaimo, J. M., Calry, B. M , Via, D. F., Conveney, E., Pappas, T. N., and Lyerly, K. H. Direct enzyme pro-drug gene therapy for pancreatic cancer in vivo. Surgery, 64: 205-213, 1994.
31. Ezzedine, Z. D., Martuza, R. L., Platika, D , Short, M. P., Malik, A., Choi, B., and Breakfield, X. O. Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biol., 3. 608-614, 1991.
32. Harris, J. D., Guitierrez, A. A , Hurst, H. C., Sikora, K., and Lemoine, N. R Gene therapy for cancer using tumor specific prodrug activation. Gene Ther., 1. 46-50, 1994.
33. Hirschowitz, E. A., Ohwada, A., Pascal, W. R., Russi, T. J , and Crystal, R. G. in vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma derived tumors induces chemosensitivity to 5-fluorocytosine. Hum. Gene Ther., 6: 1055-1063, 1995.
34. Wei, M. X., Tamiya, T., Chase, M., Boviatsis, E. J., Chang, T. K., Kowall, N. W., Hochberg, F. H., Waxraan, D. J., and Breakefield, X. O Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome p450 2BI gene. Hum. Gene Ther., 5: 969-978, 1994.
35. Chen, L., and Waxman, D. J. Intratumoral activation and enhanced chemotherapeutic effect of oxazophorines following cylochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res., 55: 581-589, 1995.
36. Fujiwara, T., Grimm, E. A., Mukhopadhyay, T., Zhang, W. W., Owen-Schaub, L. B., and Roth, J. A. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res., 54: 2287-2291, 1994.
37. Fan, S., Smith, M. L., Rivet, D. J., Duba. D., Zhan, Q., Kohn, K. W., Fornace, A J., and O'Conner, P. M. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res., 55: 1649-1654, 1995.